No Data
BASECARE-B: ANNUAL REPORT 2024
BaseCare Medical (2170.HK) Unveils First Smart Home Sperm Analyzer, Pioneering "B+C" Full-Scenario Intelligent Expansion
The Asia Vets home semen testing device has been approved for market launch, and Beikang Medical (2170.HK) has taken the lead in achieving "B+C" smart full-scenario coverage expansion.
Recently, Beikang Medical, the first stock focused on the entire Industry Chain of reproductive health and Assisted Reproduction IVD, announced good news: the portable home sperm quality analyzer (model: BKP200) has officially obtained its medical instrument registration certificate. As a home active sperm testing device for Consumer use in China, the approval of this product not only marks a significant technological breakthrough for Beikang Medical in the field of male reproductive health but also opens up a new growth track for the home Medical Devices market. Statistics from Guangdong Reproductive Hospital show that in the past three years, the failure rate for couples wanting to have a Two-child-related has been close to 50%; among males preparing for conception for the first time, one-third of their sperm do not meet the standards. With so many problems, many people are affected because of
BASECARE-B (02170.HK): Portable sperm quality analyzer received the medical instruments registration certificate issued by Jiangsu Medical Products Administration.
Gelonghui reported on April 8th that BASECARE-B (02170.HK) announced that the company’s portable sperm quality analyzer received a medical instruments registration certificate from the Jiangsu Province Drug Supervision Administration on April 7, 2025 (Registration No.: Su Xie Zhu Zheng 20252220581). The company's portable sperm quality analyzer is a home-use live sperm testing device aimed at the Consumer market, specifically designed for male fertility health, and adheres to the sperm quality testing standards set out in the "World Health Organization Laboratory Manual for the Examination and Processing of Human Semen (6th Edition)." This device is compact and convenient, allowing users to independently complete rapid and accurate testing at home.
Express News | Suzhou Basecare Medical Corp - Jiangsu Mpa Approval of Registration Application for Portable Sperm Quality Analyzer
Revenue surged by 44%, Beikang Medical (2170.HK) is moving toward Global smart manufacturing.
In light of the frequent positive news about fertility, Beikang Medical, the first stock in Assisted Reproduction IVD focused on the entire Industry Chain of fertility health, has released its 2024 annual report, showcasing impressive performance. The company achieved nearly 0.3 billion yuan in revenue for the year, with an astonishing year-on-year increase of 44%, marking the initial success of its Global Strategy deployment in the international Industry Chain, and it is expected to grow into one of the most innovative companies in the Global Assisted Reproduction field. In response to issues such as fertility challenges and the high cost of raising children, domestic Assisted Reproduction services have been fully incorporated into the Insurance system, and related child-rearing subsidy policies are also accelerating. Meanwhile, the USA White House has signed an executive order to strengthen Medical insurance coverage for fertility, clearly requiring that commercial insurance plans must...
